

Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)

NCT06563323

Status	RECRUITING
Phase	Phase 2
Sponsor	Oregon Health and Science University
Enrollment	17 participants

Key Eligibility Criteria

Inclusion (9)

- Willingness to comply with study procedures/requirements
- Capable of giving informed consent
- Diagnosis of at least one PG ulcer by clinical, histological and laboratory assessments with a minimum wound size of 4 cm².
- Undergoing at least once a week standard of care wound care at home or at a wound care facility
- Are candidate for systemic therapy. Must be on a stable dose of prednisone of 20 mg/day for at least two weeks prior to first drug administration.

... and 4 more (see full listing online)

Exclusion (31)

- Has previously received at any time any therapeutic agent directly targeted to IL-23 including, but not limited to, guselkumab, risankizumab, tildrakuzumab, or mirikizumab
- Any drug treatment specifically for PG including but not limited to biologics (or biosimilar of), experimental antibodies, small molecules and oral immunosuppressives used within washout periods specified below, prior to first dose of study drug:
 - weeks for ustekinumab, ixekizumab, secukinumab, brodalumab;
 - weeks for infliximab;
 - weeks for adalimumab;

... and 26 more (see full listing online)

Locations (2 total)

Ohio State Dermatology, Columbus, Ohio, United States
Oregon Health and Science University, Portland, Oregon, United States

<https://clinicaltrials.gov/study/NCT06563323>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).